|
Real-time
Euronext Paris
04:38:24 2026-08-13 EDT
|
5-day change | 1st Jan Change | ||
| 13.38 EUR | +1.98% |
|
-2.48% | +154.13% |
| 07-03 | Genfit soars on news of U.S. reimbursement for a product |  |
| 07-03 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 758M | |||||
| 48.72B | |||||
| 43.99B | - | - | - | - | - |
| 40.82B | |||||
| 39.79B | |||||
| 32.7B |
- Stock Market
- Stocks
- GNFT Stock
- Charts GENFIT
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
